Triple-Blind study of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

This appears to be a biological / biomarker / imaging study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

You may need to provide biological samples, complete lab tests, or take part in imaging or measurement procedures. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

If the study involves samples, imaging, or biomarkers, ask what is collected, how it is stored, who can access results, whether there may be discomfort, and whether results are shared with you. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by Hospital de Clinicas de Porto Alegre, which appears to be a hospital or academic medical center. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts.